

REMARKS

Upon entry of the amendment, claims 18, 39-53 and 55-65 will be pending in the application. Support for the amendment to claims 18, 43-51, 58, 60 and 61 appears in the specification at, e.g., page 23, lines 5-22. Support for the amendment to claim 59 appears in claim 58. No new matter has been added.

The pending claims have been amended to require that the recited antibody specifically binds to an epitope in a human IL-11 Receptor (IL-11R) protein. The claims further require that the human IL-11R protein comprise an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422. Thus, the presently claimed antibody expressly excludes antibodies that bind to a polypeptide or moiety other than an IL-11 Receptor polypeptide.

The application is believed in condition for allowance, and such action is respectfully requested. The Commissioner is authorized to charge any fees that may be due, or credit any overpayments of same, to Deposit Account No. 50-0311, Ref. No. 22058-516 DIV CON.

Respectfully submitted,

David E. Johnson, Reg. No. 41,874
Janiné M. Susan, Reg. No. 46,149
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer Number 30623

Dated: March 14, 2004